RZLT_OUT_1 [2025-04-24 05:41:10 -0400] 5776 Bytes | 1555 tokens | Cum: 1555 tkns (19.44% of 8k)
==========================================================================

We're scouting for winners today. Its 5:41 AM on Thu Apr 24, 2025 and I'm looking at Rezolute (RZLT) up to $4.00 from $3.11

Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.

--- COMPANY PROFILE ---
Company: Rezolute (RZLT)
IPO: 2011-12-23 (13 Years Ago)
Market Cap: $147,403,760
Shares Outstanding: 60,540,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.

Here’s a list of headlines for Rezolute:

Apr-23-25 08:05AM - Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants
Apr-23-25 08:05AM 08:00AM - Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism ( HI )
Apr-11-25 12:00PM - Rezolute (RZLT) Upgraded to Buy: What Does It Mean for the Stock?
Mar-26-25 07:30AM - Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors
Feb-12-25 04:05PM - Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Feb-04-25 08:00AM - Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Jan-31-25 08:00AM - Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference
Jan-07-25 08:00AM - Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
Dec-05-24 08:00AM - Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Dec-03-24 08:00AM - FDA Grants Orphan Drug Designation to Rezolute's Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Nov-07-24 04:05PM - Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
Nov-05-24 08:00AM - Rezolute to Participate in Upcoming Investor Conferences
Sep-19-24 04:05PM - Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
Sep-09-24 07:30AM - FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
Aug-27-24 08:00AM - Rezolute to Participate in Upcoming Investor Conferences
Aug-05-24 07:30AM - Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
Jul-31-24 08:00AM - Rezolute to Participate in the BTIG Virtual Biotechnology Conference
Jun-27-24 08:00AM - Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement
Jun-24-24 08:00AM - Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds
Jun-14-24 07:30AM - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Jun-13-24 11:30PM - Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
Jun-13-24 11:30PM 04:01PM - Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-06-27T12:00:00Z - Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
B2 - 2024-06-24T12:00:00Z - Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds
B3 - 2024-06-14T03:30:00Z - Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
B4 - 2024-06-13T20:01:00Z - Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
B5 - 2024-05-21T20:05:00Z - Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
B6 - 2024-05-15T20:05:00Z - Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Rezolute (RZLT).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

RZLT_OUT_3 [2025-04-24 05:41:11 -0400] 768 Bytes | 218 tokens | Cum: 1775 tkns (22.19% of 8k)
==========================================================================

Showing B5 (chunk 1 of 1): B5:
**Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/05/21/2886029/0/en/Rezolute-Reports-Positive-Topline-Results-from-Phase-2-Proof-of-Concept-Study-of-RZ402-in-Patients-with-Diabetic-Macular-Edema-DME.htmlMet primary study endpoints: good safety profile and reduction in central subfield thickness (CST)

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RZLT_OUT_5 [2025-04-24 05:41:11 -0400] 955 Bytes | 287 tokens | Cum: 2064 tkns (25.80% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-23T21:03:00Z - Rezolute Prices $90 Mln Offering With Common Stock And Pre-Funded Warrants...
A2 - 2025-04-23T19:50:43Z - Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In Decem...
A3 - 2025-04-23T16:46:00Z - Rezolute Raises $90 Mln Through Stock And Warrant Offering To Support HI Drug Pipeline...
A4 - 2025-04-23T15:50:54Z - Rezolute Gets Positive DMC Review For Phase 3 Ersodetug Trial In Congenital HI...
A5 - 2025-04-23T15:57:00Z - Rezolute Gets Positive DMC Review For Phase 3 Ersodetug Trial In Congenital HI...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

RZLT_OUT_7 [2025-04-24 05:41:12 -0400] 1181 Bytes | 308 tokens | Cum: 2374 tkns (29.68% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**Rezolute Prices $90 Mln Offering With Common Stock And Pre-Funded Warrants**Date: 2025-04-23Source: {'uri': 'nasdaq.com', 'dataType': 'news', 'title': 'NASDAQ Stock Market'}URL: https://www.nasdaq.com/articles/rezolute-prices-90-mln-offering-common-stock-and-pre-funded-warrants(RTTNews) - Rezolute, Inc. (RZLT), a late-stage biopharmaceutical company focused on rare disease treatments, announced the pricing of an underwritten public offering.

The offering includes approximately 20.8 million shares of common stock at $3.25 per share, along with pre-funded warrants for 6.9 million shares offered at $3.249 per warrant. Combined, the gross proceeds are expected to total around $90 million before expenses. The company has also granted underwriters a 30-day option to purchase up to 4.15 million additional shares.

All securities in the offering will be issued by Rezolute, with the closin

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RZLT_OUT_9 [2025-04-24 05:41:13 -0400] 1181 Bytes | 274 tokens | Cum: 2650 tkns (33.12% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): g anticipated around April 24, 2025, pending customary conditions. The deal includes backing from both new and existing institutional investors such as Federated Hermes Kaufmann Funds, Blackstone Multi-Asset Investing, and Nantahala Capital.

Rezolute plans to use the proceeds for R&D, general corporate purposes, and working capital. The securities are offered under a shelf registration statement filed with and declared effective by the SEC in November 2023. The offering will be conducted via a prospectus supplement available through the SEC's website or directly from the underwriters.

Wednesday, RZLT closed at $3.97, marking a 27.65% decline. In after-hours trading, the stock edged up slightly to $3.98, reflecting a 0.25% increase on the Nasdaq Capital Market.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasda

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RZLT_OUT_11 [2025-04-24 05:41:14 -0400] 290 Bytes | 87 tokens | Cum: 2739 tkns (34.24% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): q, Inc.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RZLT_OUT_13 [2025-04-24 05:41:15 -0400] 838 Bytes | 222 tokens | Cum: 2963 tkns (37.04% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-23 8-K Item 7.01 Regulation FD Disclosure.

On April 23, 2025, Rezolute, Inc. (the Company ) issued a press release (the Interim Analysis Press Release ) announcing a positive recommendation received after an independent interim analysis of the Companys Phase 3 sunRize study. A copy of...

S2 - 2025-04-23 8-K Item 1.01. Entry into a Material Definitive Agrmt.

Registered Direct Offering

On April 23, 2025, Rezolute, Inc. (the Company ) entered into an underwriting agreement (the Underwriting Agrmt ) with Guggenheim Securities, LLC ( Guggenheim Securities ), as representative...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

RZLT_OUT_15 [2025-04-24 05:41:16 -0400] 1178 Bytes | 288 tokens | Cum: 3253 tkns (40.66% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item 7.01 Regulation FD Disclosure.

On April 23, 2025, Rezolute, Inc. (the Company ) issued a press release (the Interim Analysis Press Release ) announcing a positive recommendation received after an independent interim analysis of the Companys Phase 3 sunRize study. A copy of the Interim Analysis Press Release is attached hereto as Exhibit 99.1.

The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act ), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

RZLT_OUT_17 [2025-04-24 05:41:24 -0400] 7074 Bytes | 2011 tokens | Cum: 5266 tkns (65.83% of 8k)
==========================================================================

This is our set of metrics for Rezolute.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+----------------------+
| Volume: 16,931,658 | Perf Month: 31.02% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+-------------------------+----------------------+
| Avg Volume: 857.53K | Perf Quarter: -17.46% | Short Float: 4.57% | ROE: -74.36% |
+---------------------+-----------------------+-------------------------+----------------------+
| Rel Volume: 25.80 | Index: - | Short Ratio: 2.63 | ROI: -70.48% |
+---------------------+-----------------------+-------------------------+----------------------+
| RSI (14): 69.65 | Market Cap: 240.33M | Short Interest: 2.26M | Sales Surprise: - |
+---------------------+-----------------------+-------------------------+----------------------+
| ATR (14): 0.36 | Shs Outstand: 60.53M | Beta: 0.90 | EPS Surprise: 12.00% |
+---------------------+-----------------------+-------------------------+----------------------+
| SMA20: 40.96% | Shs Float: 49.45M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+-------------------------+----------------------+
| SMA50: 12.85% | Inst Own: 69.15% | Sales past 5Y: 0.00% | Earnings: Feb 12 AMC |
+---------------------+-----------------------+-------------------------+----------------------+
| SMA200: -12.33% | Insider Own: 18.32% | Employees: 59 | |
+---------------------+-----------------------+-------------------------+----------------------+
| Perf Week: 51.53% | Insider Trans: 13.61% | Debt/Eq: 0.02 | |
+---------------------+-----------------------+-------------------------+----------------------+

The next section covers any insider trading by Rezolute officers or majority shareholders (if available).

Inside Trans: Rezolute, Inc. (RZLT) by Hogenhuis Wladimir (Unknown Title) on 2025-04-01
- Common Shares: 6758 shares at $2.92 (D)

Inside Trans: Rezolute, Inc. (RZLT) by Elam Nevan C (CEO) on 2025-03-27
- Common Shares: 12302 shares at $2.845 (D)

Inside Trans: Rezolute, Inc. (RZLT) by Evans Daron (CFO) on 2025-03-26
- Common Shares: 10000 shares at $2.89 (D)
- Common Shares: 10000 shares at $2.88 (I)

No transactions recorded.

Inside Trans: Rezolute, Inc. (RZLT) by Harris Erik (Unknown Title) on 2025-03-25
- Director Stock Option (Right to Buy): 60000 shares at $0 (D)

Inside Trans: Rezolute, Inc. (RZLT) by Labrucherie Gil M (Unknown Title) on 2025-02-16
- Common Shares: 25500 shares at $0 (D)
- Director Stock Option (Right to Buy): 15000 shares at $0 (D)

Inside Trans: Rezolute, Inc. (RZLT) by Hogenhuis Wladimir (Unknown Title) on 2025-02-16
- Common Shares: 25500 shares at $0 (D)
- Common Shares: 10000 shares at $4.7 (D)
- Director Stock Option (Right to Buy): 15000 shares at $0 (D)

Inside Trans: Rezolute, Inc. (RZLT) by ROBERTS BRIAN KENNETH (Chief Medical Officer) on 2025-02-16
- Common Shares: 77000 shares at $0 (D)
- Employee Stock Option (Right to Buy): 45000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -71134000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 3.97
Average Volume: 1605214.67
30-Day High: 3.97
30-Day Low: 2.47

[Detailed Financials: Q2 2025]
- Total Assets: $112,007,000.00
- Total Liabilities: $12,418,000.00
- Total Equity: $99,589,000.00
- Current Assets: $98,694,000.00
- Current Liabilities: $10,608,000.00

[Income Statement: Q2 2025]
- Revenue: $0.00
- Net Income: $-15,730,000.00
- Gross Profit: N/A
- Operating Income: $-17,080,000.00
- Earnings Per Share (EPS): -0.22

[Cash Flow Statement: Q2 2025]
- Net Cash Flow: $-1,540,000.00

[Detailed Financials: Q1 2025]
- Total Assets: $123,414,000.00
- Total Liabilities: $9,973,000.00
- Total Equity: $113,441,000.00
- Current Assets: $110,178,000.00
- Current Liabilities: $7,991,000.00

[Income Statement: Q1 2025]
- Revenue: $0.00
- Net Income: $-15,378,000.00
- Gross Profit: N/A
- Operating Income: $-16,941,000.00
- Earnings Per Share (EPS): -0.22

[Cash Flow Statement: Q1 2025]
- Net Cash Flow: $-59,924,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Rezolute (RZLT).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Rezolute.

2) MARKET_SCORE[]
This conversation was initiated because RZLT is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for RZLT.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, RZLT could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect RZLT to increase 50% from its current price of $2.57, say: PRICE_TARGET[3.85]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Rezolute.

11) ETHICAL_RATING[]
Rate Rezolute’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Rezolute.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

RZLT_IN_19 [2025-04-24 05:41:24 -0400] 126 Bytes | 29 tokens | Cum: 5504 tkns (68.80% of 8k)
==========================================================================

====================================
[2025-04-24 05:41:24] # Analysis Completed
Elapsed Time: 15.10 seconds